Pancragen in Australia: legal status and listed suppliers

Legal status in Australia

Not an approved medicine. Not listed by name in the Poisons Standard (June 2026).

As understood at 2026-09-22. Verify with the TGA.

What Pancragen is

Pancragen is a synthetic four-amino-acid peptide (Lys-Glu-Asp-Trp) from the Khavinson series of bioregulator peptides, designed from a peptide extract of pancreatic tissue. All published research is from the developing institute and none is in humans.

Full Pancragen page: targets and research →

Listed suppliers in Australia

None of the suppliers we list in Australia list Pancragen.

Clinical Research

Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus

Khavinson VKh, Gavrisheva NA, Malinin VV, Chefu SG, Trofimov EL (2007). Bulletin of Experimental Biology and Medicine. animal Wistar rats with streptozotocin-induced diabetes

Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys

Goncharova ND, Ivanova LG, Oganyan TE, Vengerin AA, Khavinson VK (2015). Advances in Gerontology (Uspekhi Gerontologii). animal old female rhesus monkeys (20–25 years), n=9 (5 pancragen, 4 glimepiride)

Effects of pancragen on the differentiation of pancreatic cells during their ageing

Khavinson VKh, Durnova AO, Polyakova VO, et al. (2013). Bulletin of Experimental Biology and Medicine. in-vitro 'young' and 'aged' pancreatic cell cultures

Study of biological activity of Lys-Glu-Asp-Trp-NH2 endogenous tetrapeptide

Khavinson VKh, Gapparov MM, Sharanova NE, Vasilyev AV, Ryzhak GA (2010). Bulletin of Experimental Biology and Medicine. animal rats during development and with streptozotocin-induced diabetes

Study of interactions between DNA and tetrapeptides using methods of molecular mechanics

Tarnovskaya SI, Yakutseni PP, Khavinson VKh (2014). Bulletin of Experimental Biology and Medicine. in-vitro computational molecular modelling; no cells or animals